 Shandra Knight
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 15 | 2024 | 610 | 1.900 |
Why?
| | Scleroderma, Systemic | 6 | 2024 | 114 | 1.230 |
Why?
| | Idiopathic Pulmonary Fibrosis | 7 | 2022 | 634 | 0.760 |
Why?
| | Alveolitis, Extrinsic Allergic | 4 | 2021 | 97 | 0.650 |
Why?
| | Mycobacterium kansasii | 3 | 2020 | 15 | 0.520 |
Why?
| | Mycobacterium Infections, Nontuberculous | 4 | 2022 | 353 | 0.500 |
Why?
| | Mycobacterium abscessus | 3 | 2020 | 107 | 0.450 |
Why?
| | Lung | 11 | 2024 | 3938 | 0.330 |
Why?
| | Bacteriuria | 2 | 2019 | 9 | 0.320 |
Why?
| | Asymptomatic Infections | 2 | 2019 | 26 | 0.310 |
Why?
| | Injections | 2 | 2019 | 174 | 0.290 |
Why?
| | Administration, Intravenous | 2 | 2019 | 141 | 0.290 |
Why?
| | Drug Utilization | 2 | 2019 | 171 | 0.290 |
Why?
| | Pulmonary Fibrosis | 2 | 2022 | 385 | 0.280 |
Why?
| | Urinary Tract Infections | 2 | 2019 | 151 | 0.280 |
Why?
| | Disease Management | 3 | 2019 | 588 | 0.270 |
Why?
| | Societies, Medical | 4 | 2023 | 744 | 0.250 |
Why?
| | Anti-Infective Agents | 2 | 2019 | 247 | 0.250 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2016 | 49 | 0.250 |
Why?
| | Outpatients | 2 | 2019 | 373 | 0.240 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 115 | 0.240 |
Why?
| | Biopsy | 7 | 2022 | 1088 | 0.230 |
Why?
| | Cross Infection | 2 | 2016 | 217 | 0.220 |
Why?
| | Indoles | 2 | 2024 | 383 | 0.220 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 984 | 0.200 |
Why?
| | Immunosuppressive Agents | 5 | 2024 | 858 | 0.190 |
Why?
| | Lymphocytes | 2 | 2020 | 378 | 0.190 |
Why?
| | Disease Progression | 6 | 2024 | 2627 | 0.180 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 646 | 0.180 |
Why?
| | Hypercapnia | 1 | 2020 | 50 | 0.170 |
Why?
| | Humans | 36 | 2024 | 129626 | 0.170 |
Why?
| | Bronchoscopy | 4 | 2022 | 216 | 0.160 |
Why?
| | Inhalation Exposure | 1 | 2020 | 91 | 0.160 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1501 | 0.160 |
Why?
| | Gastroesophageal Reflux | 1 | 2022 | 232 | 0.160 |
Why?
| | Immunoglobulin G | 2 | 2021 | 851 | 0.160 |
Why?
| | Noninvasive Ventilation | 1 | 2020 | 49 | 0.160 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2020 | 143 | 0.160 |
Why?
| | Cyclophosphamide | 3 | 2024 | 234 | 0.160 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2020 | 83 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 757 | 0.150 |
Why?
| | Nontuberculous Mycobacteria | 4 | 2022 | 204 | 0.150 |
Why?
| | Home Care Services | 1 | 2020 | 225 | 0.140 |
Why?
| | Liver Diseases | 1 | 2020 | 290 | 0.140 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 712 | 0.130 |
Why?
| | Neurocognitive Disorders | 1 | 2016 | 26 | 0.130 |
Why?
| | Anti-Bacterial Agents | 4 | 2019 | 1705 | 0.130 |
Why?
| | Cardiomyopathies | 1 | 2020 | 340 | 0.130 |
Why?
| | Kidney Diseases | 1 | 2020 | 383 | 0.130 |
Why?
| | Mycobacterium avium Complex | 3 | 2020 | 88 | 0.120 |
Why?
| | Quality of Life | 5 | 2024 | 2688 | 0.120 |
Why?
| | Lung Diseases | 1 | 2022 | 741 | 0.120 |
Why?
| | United States | 9 | 2024 | 13871 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2022 | 2512 | 0.110 |
Why?
| | Adult | 13 | 2022 | 35599 | 0.110 |
Why?
| | Rituximab | 2 | 2024 | 164 | 0.100 |
Why?
| | Influenza, Human | 1 | 2019 | 601 | 0.100 |
Why?
| | Antacids | 2 | 2022 | 16 | 0.100 |
Why?
| | Hypertension, Pulmonary | 2 | 2021 | 1894 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2016 | 275 | 0.090 |
Why?
| | Americas | 2 | 2019 | 24 | 0.080 |
Why?
| | Neutropenia | 2 | 2019 | 137 | 0.070 |
Why?
| | Drug Therapy | 2 | 2019 | 80 | 0.070 |
Why?
| | Transplant Recipients | 2 | 2019 | 163 | 0.070 |
Why?
| | HIV Infections | 1 | 2022 | 2730 | 0.070 |
Why?
| | Societies | 2 | 2017 | 39 | 0.070 |
Why?
| | Antimicrobial Stewardship | 2 | 2019 | 107 | 0.070 |
Why?
| | Communicable Diseases | 2 | 2019 | 152 | 0.070 |
Why?
| | Asthma | 1 | 2020 | 2225 | 0.060 |
Why?
| | Drug Resistance, Multiple, Bacterial | 2 | 2016 | 71 | 0.060 |
Why?
| | Bacteriological Techniques | 2 | 2016 | 69 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2006 | 0.050 |
Why?
| | Lung Volume Measurements | 1 | 2023 | 45 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2024 | 110 | 0.050 |
Why?
| | Vital Capacity | 1 | 2024 | 289 | 0.050 |
Why?
| | Spirometry | 1 | 2023 | 255 | 0.050 |
Why?
| | Prevalence | 2 | 2019 | 2564 | 0.050 |
Why?
| | Dyspnea | 1 | 2024 | 239 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2023 | 581 | 0.050 |
Why?
| | Prospective Studies | 2 | 2024 | 7135 | 0.040 |
Why?
| | Bronchial Provocation Tests | 1 | 2021 | 51 | 0.040 |
Why?
| | Pyridones | 1 | 2022 | 158 | 0.040 |
Why?
| | Serologic Tests | 1 | 2020 | 52 | 0.040 |
Why?
| | Bronchoalveolar Lavage | 1 | 2020 | 92 | 0.040 |
Why?
| | Lymphadenopathy | 1 | 2020 | 9 | 0.040 |
Why?
| | Mediastinum | 1 | 2020 | 24 | 0.040 |
Why?
| | Hypercalcemia | 1 | 2020 | 21 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 110 | 0.040 |
Why?
| | Medical History Taking | 1 | 2020 | 118 | 0.040 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2020 | 58 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2020 | 88 | 0.040 |
Why?
| | Exhalation | 1 | 2020 | 39 | 0.040 |
Why?
| | Cryosurgery | 1 | 2020 | 57 | 0.040 |
Why?
| | Alkaline Phosphatase | 1 | 2020 | 146 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 2020 | 153 | 0.040 |
Why?
| | Pulmonary Medicine | 1 | 2020 | 79 | 0.040 |
Why?
| | Eye Diseases | 1 | 2020 | 82 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 618 | 0.040 |
Why?
| | Endosonography | 1 | 2020 | 141 | 0.040 |
Why?
| | Chemoprevention | 1 | 2019 | 91 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3394 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 282 | 0.040 |
Why?
| | Japan | 1 | 2018 | 98 | 0.040 |
Why?
| | Latin America | 1 | 2018 | 87 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5415 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 490 | 0.040 |
Why?
| | Sarcoidosis | 1 | 2020 | 156 | 0.040 |
Why?
| | Hemorrhage | 1 | 2022 | 680 | 0.040 |
Why?
| | Europe | 1 | 2018 | 363 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2020 | 472 | 0.030 |
Why?
| | Eosinophils | 1 | 2020 | 324 | 0.030 |
Why?
| | Genomics | 1 | 2022 | 718 | 0.030 |
Why?
| | Echocardiography | 1 | 2020 | 634 | 0.030 |
Why?
| | Electrocardiography | 1 | 2020 | 611 | 0.030 |
Why?
| | Vitamin D | 1 | 2020 | 381 | 0.030 |
Why?
| | Pregnancy | 2 | 2019 | 6417 | 0.030 |
Why?
| | Seasons | 1 | 2019 | 494 | 0.030 |
Why?
| | Aged | 3 | 2020 | 22061 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2020 | 524 | 0.030 |
Why?
| | Disease Outbreaks | 1 | 2019 | 349 | 0.030 |
Why?
| | Hemodynamics | 1 | 2021 | 1090 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2024 | 14522 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1365 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2020 | 895 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1720 | 0.030 |
Why?
| | Calcium | 1 | 2020 | 1212 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1432 | 0.030 |
Why?
| | Time Factors | 1 | 2020 | 6555 | 0.020 |
Why?
| | Child | 2 | 2019 | 20884 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 7052 | 0.020 |
Why?
| | Male | 3 | 2020 | 63670 | 0.020 |
Why?
| | Female | 3 | 2020 | 68734 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2016 | 10219 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 20412 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 31136 | 0.010 |
Why?
|
|
Knight's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|